Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)

Abstract Obesity and cirrhosis are associated with poor hepatitis B virus (HBV) vaccine responses, but vaccine efficacy has not been assessed in nonalcoholic fatty liver disease (NAFLD). Sixty-eight HBV-naïve adults with NAFLD were enrolled through the Canadian HBV network and completed three-dose H...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shivali S. Joshi, Rachelle P. Davis, Mang M. Ma, Edward Tam, Curtis L. Cooper, Alnoor Ramji, Erin M. Kelly, Saumya Jayakumar, Mark G. Swain, Craig N. Jenne, Carla S. Coffin
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d4dddf359a0648d181b13bb455e83642
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d4dddf359a0648d181b13bb455e83642
record_format	dspace
spelling	oai:doaj.org-article:d4dddf359a0648d181b13bb455e836422021-12-02T14:12:07ZReduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)10.1038/s41541-020-00266-42059-0105https://doaj.org/article/d4dddf359a0648d181b13bb455e836422021-01-01T00:00:00Zhttps://doi.org/10.1038/s41541-020-00266-4https://doaj.org/toc/2059-0105Abstract Obesity and cirrhosis are associated with poor hepatitis B virus (HBV) vaccine responses, but vaccine efficacy has not been assessed in nonalcoholic fatty liver disease (NAFLD). Sixty-eight HBV-naïve adults with NAFLD were enrolled through the Canadian HBV network and completed three-dose HBV or HBV/HAV vaccine (Engerix-B®, or Twinrix®, GlaxoSmithKline). Anti-HBs titers were measured at 1–3 months post third dose. In 31/68 subjects enrolled at the coordinating-site, T-cell proliferation and follicular T-helper cells (pTFH) were assessed using PBMC. Immune response was also studied in NAFLD mice. NAFLD patients were stratified as low-risk-obesity, BMI < 35 (N = 40) vs. medium-high-risk obesity, BMI > 35 (N = 28). Anti-HBs titers were lower in medium/high-risk obesity, 385 IU/L ± 79 vs. low-risk obesity class, 642 IU/L ± 68.2, p = 0.02. High-risk obesity cases, N = 14 showed lower vaccine-specific-CD3+ CD4+ T-cell response compared to low-risk obesity patients, N = 17, p = 0.02. Low vaccine responders showed dysfunctional pTFH. NAFLD mice showed lower anti-HBs levels and T-cell response vs. controls. In conclusion, we report here that obese individuals with NAFLD exhibit decreased HBV vaccine-specific immune responses.Shivali S. JoshiRachelle P. DavisMang M. MaEdward TamCurtis L. CooperAlnoor RamjiErin M. KellySaumya JayakumarMark G. SwainCraig N. JenneCarla S. CoffinNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Shivali S. Joshi Rachelle P. Davis Mang M. Ma Edward Tam Curtis L. Cooper Alnoor Ramji Erin M. Kelly Saumya Jayakumar Mark G. Swain Craig N. Jenne Carla S. Coffin Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)
description	Abstract Obesity and cirrhosis are associated with poor hepatitis B virus (HBV) vaccine responses, but vaccine efficacy has not been assessed in nonalcoholic fatty liver disease (NAFLD). Sixty-eight HBV-naïve adults with NAFLD were enrolled through the Canadian HBV network and completed three-dose HBV or HBV/HAV vaccine (Engerix-B®, or Twinrix®, GlaxoSmithKline). Anti-HBs titers were measured at 1–3 months post third dose. In 31/68 subjects enrolled at the coordinating-site, T-cell proliferation and follicular T-helper cells (pTFH) were assessed using PBMC. Immune response was also studied in NAFLD mice. NAFLD patients were stratified as low-risk-obesity, BMI < 35 (N = 40) vs. medium-high-risk obesity, BMI > 35 (N = 28). Anti-HBs titers were lower in medium/high-risk obesity, 385 IU/L ± 79 vs. low-risk obesity class, 642 IU/L ± 68.2, p = 0.02. High-risk obesity cases, N = 14 showed lower vaccine-specific-CD3+ CD4+ T-cell response compared to low-risk obesity patients, N = 17, p = 0.02. Low vaccine responders showed dysfunctional pTFH. NAFLD mice showed lower anti-HBs levels and T-cell response vs. controls. In conclusion, we report here that obese individuals with NAFLD exhibit decreased HBV vaccine-specific immune responses.
format	article
author	Shivali S. Joshi Rachelle P. Davis Mang M. Ma Edward Tam Curtis L. Cooper Alnoor Ramji Erin M. Kelly Saumya Jayakumar Mark G. Swain Craig N. Jenne Carla S. Coffin
author_facet	Shivali S. Joshi Rachelle P. Davis Mang M. Ma Edward Tam Curtis L. Cooper Alnoor Ramji Erin M. Kelly Saumya Jayakumar Mark G. Swain Craig N. Jenne Carla S. Coffin
author_sort	Shivali S. Joshi
title	Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)
title_short	Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)
title_full	Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)
title_fullStr	Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)
title_full_unstemmed	Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)
title_sort	reduced immune responses to hepatitis b primary vaccination in obese individuals with nonalcoholic fatty liver disease (nafld)
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/d4dddf359a0648d181b13bb455e83642
work_keys_str_mv	AT shivalisjoshi reducedimmuneresponsestohepatitisbprimaryvaccinationinobeseindividualswithnonalcoholicfattyliverdiseasenafld AT rachellepdavis reducedimmuneresponsestohepatitisbprimaryvaccinationinobeseindividualswithnonalcoholicfattyliverdiseasenafld AT mangmma reducedimmuneresponsestohepatitisbprimaryvaccinationinobeseindividualswithnonalcoholicfattyliverdiseasenafld AT edwardtam reducedimmuneresponsestohepatitisbprimaryvaccinationinobeseindividualswithnonalcoholicfattyliverdiseasenafld AT curtislcooper reducedimmuneresponsestohepatitisbprimaryvaccinationinobeseindividualswithnonalcoholicfattyliverdiseasenafld AT alnoorramji reducedimmuneresponsestohepatitisbprimaryvaccinationinobeseindividualswithnonalcoholicfattyliverdiseasenafld AT erinmkelly reducedimmuneresponsestohepatitisbprimaryvaccinationinobeseindividualswithnonalcoholicfattyliverdiseasenafld AT saumyajayakumar reducedimmuneresponsestohepatitisbprimaryvaccinationinobeseindividualswithnonalcoholicfattyliverdiseasenafld AT markgswain reducedimmuneresponsestohepatitisbprimaryvaccinationinobeseindividualswithnonalcoholicfattyliverdiseasenafld AT craignjenne reducedimmuneresponsestohepatitisbprimaryvaccinationinobeseindividualswithnonalcoholicfattyliverdiseasenafld AT carlascoffin reducedimmuneresponsestohepatitisbprimaryvaccinationinobeseindividualswithnonalcoholicfattyliverdiseasenafld
_version_	1718391872032866304

Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)

Ejemplares similares